Mei-jung Lai

250 Wuxing Street
Taipei, TNQ 11031, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Formulation and administration timing of lipid derivatized JAK-inhibitor and corticosteroid modulate saRNA-LNP inflammation and expression.

Formulation and administration timing of lipid derivatized JAK-inhibitor and corticosteroid modulate saRNA-LNP inflammation and expression.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: October 02, 2025

Design and synthesis of polymer nanoparticles with pH-responsive pan-HDAC inhibitor (C5) derived from norbornene block copolymers to increase C5 solubility and improve its targeted delivery to prostate cancer sites.

Design and synthesis of polymer nanoparticles with pH-responsive pan-HDAC inhibitor (C5) derived from norbornene block copolymers to increase C5 solubility and improve its targeted delivery to prostate cancer sites.

Journal: Journal of enzyme inhibition and medicinal chemistry

Published: July 23, 2025

Repurposing Linezolid in Conjunction with Histone Deacetylase Inhibitor Access in the Realm of Glioblastoma Therapies.

Repurposing Linezolid in Conjunction with Histone Deacetylase Inhibitor Access in the Realm of Glioblastoma Therapies.

Journal: Journal of medicinal chemistry

Published: January 21, 2025

Syntheses of LSD1/HDAC Inhibitors with Demonstrated Efficacy against Colorectal Cancer: In Vitro and In Vivo Studies Including Patient-Derived Organoids.

Syntheses of LSD1/HDAC Inhibitors with Demonstrated Efficacy against Colorectal Cancer: In Vitro and In Vivo Studies Including Patient-Derived Organoids.

Journal: Journal of medicinal chemistry

Published: September 25, 2024

HSP90/LSD1 dual inhibitors against prostate cancer as well as patient-derived colorectal organoids.

HSP90/LSD1 dual inhibitors against prostate cancer as well as patient-derived colorectal organoids.

Journal: European journal of medicinal chemistry

Published: May 23, 2024

Design, synthesis, and biological evaluation of adenosine derivatives targeting DOT1L and HAT as anti-leukemia agents.

Design, synthesis, and biological evaluation of adenosine derivatives targeting DOT1L and HAT as anti-leukemia agents.

Journal: Bioorganic chemistry

Published: February 24, 2024

First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity In Vitro and In Vivo.

First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity In Vitro and In Vivo.

Journal: Journal of medicinal chemistry

Published: January 29, 2024

Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress.

Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress.

Journal: Cancer letters

Published: August 24, 2023

Anticancer Study of a Novel Pan-HDAC Inhibitor MPT0G236 in Colorectal Cancer Cells.

Anticancer Study of a Novel Pan-HDAC Inhibitor MPT0G236 in Colorectal Cancer Cells.

Journal: International journal of molecular sciences

Published: July 17, 2023

Correction to "N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of Transcription 3 (STAT3) Signaling".

Correction to "N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of Transcription 3 (STAT3) Signaling".

Journal: Journal of medicinal chemistry

Published: April 20, 2023

Design, synthesis, and biological activity of dual monoamine oxidase A and heat shock protein 90 inhibitors, N-Methylpropargylamine-conjugated 4-isopropylresorcinol for glioblastoma.

Design, synthesis, and biological activity of dual monoamine oxidase A and heat shock protein 90 inhibitors, N-Methylpropargylamine-conjugated 4-isopropylresorcinol for glioblastoma.

Journal: European journal of medicinal chemistry

Published: April 02, 2023

6-Regioisomeric 5,8-quinolinediones as potent CDC25 inhibitors against colorectal cancers.

6-Regioisomeric 5,8-quinolinediones as potent CDC25 inhibitors against colorectal cancers.

Journal: European journal of medicinal chemistry

Published: March 23, 2023

Showing 1-12 of 50

Last Updated: 09/26/2026